<DOC>
	<DOCNO>NCT01264328</DOCNO>
	<brief_summary>The clinical hypothesis study first-line treatment combination panitumumab paclitaxel provide benefit patient metastatic current Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_summary>
	<brief_title>Study Combination Panitumumab With Paclitaxel First-line Treatment Subjects With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed Inform Consent Age &gt; 18 year Histologically cytologically confirm SCCHN Diagnosis metastatic disease investigator and/or recurrent disease determine incurable surgery radiotherapy Subjects receive radiation primary therapy eligible radiation therapy treatment complete &gt; 4 week prior inclusion Subjects previously receive chemotherapy part initial multimodality treatment locally advanced disease eligible chemotherapy complete &gt; 24 week prior inclusion At least 1 unidimensionally measurable lesion ≥ 20 mm use conventional technique ≥10 mm spiral CT scan . Target lesion must choose previously irradiate field unless document tumour progression lesion prior inclusion Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 screen Haematological function : ANC ≥ 1.5 x 109 cells/L Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100 x 109/L Kidney function : Adequate renal function creatinine clearance ≥ 60 mL/min ) Liver function : AST ≤ 3 x ULN ( liver metastasis , ≤ 5 x ULN ) ALT ≤ 3 x ULN ( liver metastasis , ≤ 5 x ULN ) Bilirubin ≤ 2 x ULN Metabolic function : Magnesium ≥ low limit normal , Calcium ≥ low limit normal Documented symptomatic central nervous system metastasis Nasopharyngeal carcinoma History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis ) evidence interstitial lung disease baseline chest scan History another primary cancer , except : Curatively treat situ cervical cancer , Curatively resect nonmelanoma skin cancer Other primary solid tumour curatively treat know active disease present treatment administer ≥ 3 year prior start study treatment . In case confirmation inclusion sponsor require . Clinically significant cardiovascular disease ≤ 1 year prior start study treatment Pulmonary embolism , deep vein thrombosis , significant thromboembolic event ≤ 8 week prior start study treatment Symptomatic peripheral neuropathy Grade ≥ 2 base CTCAE v3.0 Subjects recover previous acute radiotherapyrelated toxicity ≤ grade 1 History severe skin disorder opinion investigator may interfere study conduct Known positive test human immunodeficiency virus ( HIV ) infection , hepatitis C virus , acute chronic hepatitis B infection Active infection require systemic treatment uncontrolled infection ≤ 14 day prior start study treatment History interstitial pneumonia pulmonary fibrosis sign interstitial pneumonia pulmonary fibrosis baseline chest Xray . Known allergy hypersensitivity panitumumab , study medication . Prior anti epidermal growth factor receptor ( EGFr ) antibody therapy treatment small molecule EGFr inhibitor unless receive part prior multimodality treatment complete &gt; 24 week prior start study treatment . In case , investigator confirm subject present previous cetuximabrelated infusion reaction &gt; grade 2 . Subject currently enrol ≤ 30 day since end investigational device , investigational procedure , drug study ( ) , subject receive investigational agent ( ) Subjects require use immunosuppressive agent , however , corticosteroid allow Man woman childbearing potential consent use adequate contraceptive precaution course study , 6 month last study drug administration woman , 3 month men . Female subject pregnant breastfeeding , plan become pregnant within 6 month end treatment . Major surgery require general anesthesia/ spinal anesthesia significant incision ≤ 28 day minor surgery ≤ 14 day prior start study treatment . Subjects must recover surgeryrelated toxicity . Subjects wish meet study requirement unable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Head neck cancer , panitumumab , TTCC-2009-03</keyword>
</DOC>